Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.
about
Transcriptional Targeting in Cancer Gene TherapyExpanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.Advances in preclinical investigation of prostate cancer gene therapy.Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirusLinked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenovirusesAntitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinomaNonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersAdenovirus receptors and their implications in gene deliveryArmed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells.Functions and mechanisms of action of the adenovirus E3 proteins.Replication-selective oncolytic viruses in the treatment of cancer.Gene Therapy for Human Lung Adenocarcinoma Using a Suicide Gene Driven by a Lung-Specific Promoter Delivered by JC Virus-Like ParticlesAn acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster modelThe role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.Armed replicating adenoviruses for cancer virotherapy.Adenoviral vector-based strategies for cancer therapy.Oncolytic (replication-competent) adenoviruses as anticancer agents.Characterization of Ad5 E3-14.7K, an adenoviral inhibitor of apoptosis: structure, oligomeric state, and metal binding.Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein.The non-structural protein NS-2 of Bombyx mori parvo-like virus is localized to the nuclear membrane.A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication.ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis.Tamoxifen-regulated adenoviral E1A chimeras for the control of tumor selective oncolytic adenovirus replication in vitro and in vivo.Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5.
P2860
Q24791038-EEBDEB7B-9C65-4B0B-8EF5-782FA8791976Q33622711-E6EAC3D9-BFCC-404D-AA22-C425323E93D1Q33677054-B81CED59-9F09-4BDE-975D-91B64B5F346CQ33690982-DA80F5C1-78BA-4ECB-9064-45660E325589Q33755007-854ECC51-433B-40D9-BBD4-E5C909F5B136Q33868732-B53C70DD-5033-401E-9E49-DD0BE78ABBFAQ33985663-63E93314-C1D1-41EA-A023-6A2D9288104AQ33994011-F463C3C4-36CF-41C5-953C-F59EE67A6789Q35043106-3A5A0B93-E874-453A-A394-ED5B2AC3CDD2Q35105144-1B867AA8-2DF9-4FA9-A3F3-8D9F0FD4F8E6Q35613800-07A0B2C8-D41F-4C7E-B477-6104969F727DQ35912403-C08AE48A-6FF8-4ADC-831C-DBA5137EA209Q36056773-A6434D39-EF4A-44A7-A6C2-F0597E92DC78Q36209165-DE5F0BDE-4FD9-4428-9622-DFF1DB48E8EFQ36209172-8EE07C8D-631A-411B-BFB9-1166C4634F17Q36209205-8695D757-D583-44F2-ADA6-AF9DDD51FCD4Q37185117-FA2AC36C-5A1E-429E-9B07-EC12D3260303Q37185367-F05252CD-E27A-4766-BA8A-75832C73B32FQ37386616-05603499-08F1-436A-B5D1-072BBF5DF7E3Q37409025-FA59B1F6-272B-45AA-A5BB-F7E28B4AF488Q37687415-70157377-667D-49DA-BCBD-06B99F11CD41Q38269484-1D8CF166-088C-4B2D-9D07-A373D8F0294CQ40395130-0BEA69C6-C4BC-4539-A06F-0A7FAD9F1414Q40663884-85DCE1F0-273D-4347-BF90-F6224F04F48AQ42017648-B439D137-034A-410E-AC8B-C1186DE013BEQ45864768-EDB80057-13B6-4258-BFE0-59079A9943D3Q45877985-08970D78-442E-49FC-B4B2-FCDB3F93956CQ45886514-2E703F2D-0304-435C-A867-9834631D314DQ50851488-18DA4C64-D837-4161-A3BC-F2F69C6E5367
P2860
Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Tissue-specific, tumor-selecti ...... ector for cancer gene therapy.
@ast
Tissue-specific, tumor-selecti ...... ector for cancer gene therapy.
@en
type
label
Tissue-specific, tumor-selecti ...... ector for cancer gene therapy.
@ast
Tissue-specific, tumor-selecti ...... ector for cancer gene therapy.
@en
prefLabel
Tissue-specific, tumor-selecti ...... ector for cancer gene therapy.
@ast
Tissue-specific, tumor-selecti ...... ector for cancer gene therapy.
@en
P2093
P2860
P1433
P1476
Tissue-specific, tumor-selecti ...... ector for cancer gene therapy.
@en
P2093
A E Tollefson
M Kuppuswamy
V Krougliak
P2860
P304
P356
10.1128/JVI.75.7.3314-3324.2001
P577
2001-04-01T00:00:00Z